Market Overview

Cowen and Company Reiterates Outperform Rating on Auxilium Pharmaceuticals

Related AUXL
Drug ETFs Attractive Buys On Pullback
Auxilium Pharmaceuticals, Inc. Announces XIAFLEX Now Approved For The Concurrent Treatment Of Up To Two Affected Joints In The Same Hand In Dupuytren's Contracture Patients

In a report published Monday, Cowen and Company reiterated its Outperform rating on Auxilium Pharmaceuticals (NASDAQ: AUXL).

Cowen and Company noted, “This morning in conjunction with a competitor's conference, Auxilium disclosed 2012 full year product revenues that are within the ranges of previous guidance. This is good news, as based upon prescribing trends investors had been fearful that Testim would fall short of guidance. Moreover, it appears that Q4:12 sales of Xiaflex sales were actually quite strong. We believe AUXL shares could recover substantially assuming increased investor confidence in these franchises, and believe the stock is 50% undervalued on a SOTP basis including sales of Xiaflex in Peyronie's disease.”

Auxilium Pharmaceuticals closed on Friday at $18.49.

Latest Ratings for AUXL

DateFirmActionFromTo
Oct 2014MKM PartnersDowngradesBuyNeutral
Oct 2014Mizuho SecuritiesDowngradesBuyNeutral
Sep 2014RBC CapitalDowngradesOutperformSector Perform

View More Analyst Ratings for AUXL
View the Latest Analyst Ratings

Posted-In: Cowen and CompanyAnalyst Color Reiteration Analyst Ratings

 

Related Articles (AUXL)

Around the Web, We're Loving...

Get Benzinga's Newsletters